Clinical Trial Update: GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease [Phase 2]

View source ↗

Summary

GlaxoSmithKline completed a Phase 2 dose-ranging study of GSK573719 in chronic obstructive pulmonary disease; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GSK573719

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED | Results posted: 2014-03-04